General Catalyst Group Management LLC Makes New Investment in Maze Therapeutics, Inc. $MAZE

General Catalyst Group Management LLC purchased a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 2nd quarter, Holdings Channel reports. The fund purchased 1,035,910 shares of the company’s stock, valued at approximately $30,912,000. Maze Therapeutics accounts for approximately 16.4% of General Catalyst Group Management LLC’s investment portfolio, making the stock its 4th biggest holding.

Other large investors have also modified their holdings of the company. Royal Bank of Canada raised its position in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the last quarter. California State Teachers Retirement System grew its holdings in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in Maze Therapeutics by 18.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after buying an additional 931 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Maze Therapeutics by 23.0% during the third quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock worth $135,000 after buying an additional 977 shares in the last quarter.

Maze Therapeutics Stock Down 3.3%

MAZE stock opened at $28.60 on Friday. The stock has a market capitalization of $1.59 billion, a P/E ratio of -11.35 and a beta of 2.21. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics, Inc. has a one year low of $13.77 and a one year high of $53.65. The company has a 50 day moving average price of $28.70 and a two-hundred day moving average price of $31.93.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, sell-side analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Insider Activity at Maze Therapeutics

In related news, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the transaction, the insider directly owned 26,250 shares in the company, valued at approximately $717,675. This represents a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the transaction, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This trade represents a 59.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 108,110 shares of company stock worth $3,057,531. 5.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on MAZE shares. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Maze Therapeutics has a consensus rating of “Buy” and an average target price of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.